Manufacturer of 120 Optimized Transfection Reagents and Tissue-Targeted Kits

Altogen Biosystems is a biotechnology company that develops and manufactures transfection kits for life sciences research, drug discovery and development. Altogen® In Vivo transfection reagents provide effective delivery of biomolecules into target tissues. Cell transfection kits are optimized for specific cancer cell lines and primary cell cultures.  Efficient delivery of cargo molecules (DNA, RNA, proteins) enabled by advanced reagent formulation and optimized transfection protocols. Altogen Biosystems develops new in vitro and in vivo delivery technologies by applying polymer chemistry, molecular and cell biology expertise.

Altogen Biosystems offers pre-optimized transfection kits and electroporation products for more than 120 cancer cell lines and primary cell types, and in vivo transfection reagents for tissue-targeted delivery. Altogen’s transfection reagents enable the delivery of cargo molecules, including plasmid DNA, various types of RNA (mRNA, siRNA, shRNA, microRNA), proteins, and small molecules both in vitro (cancer cell lines) and in vivo (tissue targeted reagents for animal research). Transfection is the delivery of exogenous molecules into cultured cells and is commonly used to study gene function, modulation of gene expression, biochemical mapping, and protein production. Unfortunately, no single delivery method or transfection reagent can be applied to all types of cells due to cellular cytotoxicity and transfection efficiencies vary dramatically and depend on the reagent, protocol, and cell type used.

We also offer GLP-compliant laboratory contract research services (provided by Altogen Labs). Our biology CRO services include pharm/tox studies and safety tests for IND applications, assay development (ELISA, IC50, RT-PCR), over 60 xenograft animal models, RNAi and gene silencing services. Altogen’s cell culture scientists transform cell lines of choice to stably express gene of interest via development of stable cell line in just 28 days.

As featured by Science magazine, Altogen Biosystems offers following in vivo transfection kits:

In Vivo Kidney-targeted Transfection Reagent – Targeted tissues: Kidney, Kidney Tumors
In Vivo Nanoparticle-based Transfection Reagent – Targeted tissues: Lung, Liver, Heart, Kidney, Brain, Tumors
In Vivo PEG-liposome Transfection Reagent – Targeted tissues: Spleen, Liver, Kidney, Tumors, Pancreas
In Vivo Lipid-based Transfection Reagent – Targeted tissues: Liver, Kidney, Liver Tumors, Kidney Tumors
In Vivo Pancreas-targeted Transfection Reagent – Targeted tissues: Pancreas, Pancreas Tumors
In Vivo Liver-targeted Transfection Kit – Targeted tissues: Liver, Liver Tumors

Selected citations and references (ALTOGEN® In Vivo Transfection Kits used in the following publications):

  • Nature. 2008 454(7203):523-7. Innate immunity induced by composition-dependent RIG-I …Saito et al [PDF]
  • Nature Medicine. 2016 22:1131–1139. The long noncoding RNA Chaer defines an epigenetic … Wang et al [PDF]
  • Nature Biotechnology. 2011 29(4):341-5. Delivery of siRNA to the mouse brain by … Alvarez-Erviti et al [PDF]
  • Nature Communications. 2016. miR-93 regulates Msk2-mediated chromatin remodelling … Badal et al [PDF]
  • J Cereb Blood Flow Metab. 2017. Inhibition of Src family kinases improves cognitive function … Liu et al [PDF]
  • Am J Pathol. 2016. Ubiquitin-Conjugating Enzyme 9 Phosphorylation as a Novel Mechanism … Tomasi et al [PDF]
  • J Biol Chem. 2017. Protein Phosphotyrosine Phosphatase 1B in Calpain-dependent … Zhang et al [PDF]
  • J Mol Cell Cardiol. 2015. Netrin-1 Abrogates Ischemia Reperfusion-induced Cardiac Mitochondrial … Siu et al [PDF]
  • Diabetologia. 2012 55(7):2069-79. The p47phox- and NADPH oxidase organiser 1 … Youn et al [PDF]
  • Journal of the American Society of Nephrology. 2016. TRPC6 Podocyte Surface Expression … Yu H et al [PDF]
  • Hypertension. 2014 63(2):353-61. Tissue transglutaminase contributes to … Liu et al [PDF]
  • Circulation Research. 2010 15;107(8). Kruppel-like factor-4 transcriptionally regulates … Cowan et al [PDF]
  • Hypertension. 2012 59(1):158-66. Role of uncoupled endothelial nitric oxide synthase … Gao et al [PDF]
  • Cardiovascular Research. 2016. Modulators of right ventricular apoptosis … Zungu-Edmondson et al [PDF]
  • PLoS Pathogens. 2012 8(8) Uridine composition of the poly-U/UC tract of HCV RNA … Schnell et al [PDF]
  • J Proteome Res. 2012(11) Retinal proteome analysis in a mouse model of oxygen-induced … Kim et al [PDF]
  • J Transl Med. 2010 15;8:133. Prevention of hyperglycemia-induced myocardial apoptosis … Zhang et al [PDF]
  • The Journal of Pathology. 2015. BDNF repairs podocyte damage by microRNA-mediated … Min Li et al [PDF]
  • Hypertension. 2015 65(2):430-9. Neurokinin 3 receptor and phosphocholine transferase… Parchim et al [PDF]
  • Gastroenterology. 2011 141(2) Differential type I interferon-mediated autophagic trafficking … Desai et al [PDF]
  • PLoS Pathog. 2014 10(10) Exosomes from hepatitis C infected patients transmit HCV … Bukong et al [PDF]
  • Molecular Therapy Nucleic Acids. 2017. Reverse Expression of Aging-Associated … Kim H. et al [PDF]
  • Diabetologia. 2015 Aug; 58(8): 1949–1958. Silencing of miR-195 reduces diabetic cardiomyopathy … Zheng et al [PDF]
  • J Virol. 2015; 89(23):11761-72. Mutational Disruption of cis-Acting Replication Element 2C in Smithee S et al [PDF]
  • Virus Res. 2016 Jul 15;220:136-49. Reversion to wildtype of a mutated and … Smithee et al [PDF]
  • RNA. 2010 16(11):2108-19. RNase L releases a small RNA from HCV RNA that refolds … Malathi et al [PDF]
  • Hypertension 2015. Hypoxia-independent upregulation of placental hypoxia factor-1 gene expression … Iriyama et al [PDF]

View complete list of citations and references at our Transfection Blog

Visit Altogen’s Transfection Resource: methods, protocols, stable and transient transfection, RNAi … Read more >